Clarity Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

ASX:CU6 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
23 Sep 24	BuyAU$3,755,075	Bank of America Corporation, Asset Management Arm	Company	444,419	AU$8.45
23 Sep 24	SellAU$2,097,510	Bank of America Corporation, Asset Management Arm	Company	250,293	AU$8.38
20 Sep 24	BuyAU$47,678	Merrill Lynch & Co. Inc., Banking Investments	Company	5,479	AU$8.70
20 Sep 24	SellAU$1,539,908	Merrill Lynch & Co. Inc., Banking Investments	Company	185,399	AU$8.31
17 Sep 24	BuyAU$55,557,322	Bank of America Corporation, Asset Management Arm	Company	10,426,657	AU$5.33
17 Sep 24	SellAU$42,321,738	Bank of America Corporation, Asset Management Arm	Company	7,362,426	AU$5.75
12 Sep 24	BuyAU$2,522,932	Merrill Lynch & Co. Inc., Banking Investments	Company	409,239	AU$6.16
03 Sep 24	SellAU$1,595,408	Merrill Lynch & Co. Inc., Banking Investments	Company	221,711	AU$7.20
20 May 24	BuyAU$67,997	Robert Thomas	Individual	15,908	AU$4.40
29 Apr 24	BuyAU$86,935	Robert Thomas	Individual	34,092	AU$2.55

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CU6?
Owner Type	Number of Shares	Ownership Percentage
State or Government	3,599,920	1.12%
Private Companies	35,448,462	11.1%
Institutions	41,063,288	12.8%
Individual Insiders	57,135,858	17.8%
General Public	182,963,937	57.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.1%.

Top Shareholders

Top 25 shareholders own 42.56% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
5.66%	Christopher Roberts	18,111,280	AU$72.4m	1.12%	no data
5.22%	TM Ventures Pty Ltd.	16,699,842	AU$66.8m	-11.1%	no data
4.9%	Alan Taylor	15,693,438	AU$62.8m	7.42%	no data
4.63%	The Vanguard Group, Inc.	14,834,414	AU$59.3m	0.22%	no data
3.06%	Argo Investments Limited	9,802,322	AU$39.2m	-2.49%	0.6%
2.51%	Yarrawah Pty Ltd	8,040,000	AU$32.2m	3.03%	no data
2.13%	Vantres Pty Ltd	6,812,340	AU$27.2m	-9.02%	no data
2.06%	Charles Morgan	6,600,041	AU$26.4m	0%	no data
1.89%	Matthew Harris	6,065,800	AU$24.3m	0%	no data
1.56%	Smarter Capital Pty Ltd	5,004,543	AU$20.0m	0%	no data
1.46%	Bank of America Corporation, Asset Management Arm	4,675,014	AU$18.7m	0%	no data
1.35%	Colin Biggin	4,334,085	AU$17.3m	33.4%	no data
1.22%	Kylaco Pty Ltd	3,896,280	AU$15.6m	0%	no data
1.12%	Australian Nuclear Science and Technology Organisation	3,599,920	AU$14.4m	0%	no data
1%	Guido Belgiorno-Nettis	3,210,425	AU$12.8m	3.03%	no data
0.82%	BlackRock, Inc.	2,612,711	AU$10.5m	6.76%	no data
0.36%	Robert Thomas	1,145,000	AU$4.6m	0%	no data
0.34%	Michelle Parker	1,077,710	AU$4.3m	101%	no data
0.29%	Portland Investment Counsel Inc.	929,235	AU$3.7m	132%	0.85%
0.22%	Thomas Ramdahl	720,000	AU$2.9m	38.5%	no data
0.21%	BetaShares Capital Limited	684,083	AU$2.7m	3.67%	0.01%
0.17%	Merrill Lynch & Co. Inc., Banking Investments	548,412	AU$2.2m	0%	no data
0.16%	Charles Schwab Investment Management, Inc.	518,832	AU$2.1m	0%	no data
0.11%	Norges Bank Investment Management	367,730	AU$1.5m	0%	no data
0.091%	SEI Investments Management Corporation	290,534	AU$1.2m	185%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/24 13:28
End of Day Share Price	2024/12/24 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Clarity Pharmaceuticals Ltd is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Hester	Bell Potter
Madeleine Williams	Canaccord Genuity
David Stanton	Jefferies LLC